D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder
Abstract
Obsessive-compulsive disorder is a common, chronic, and oftentimes disabling disorder. The only established first-line treatments for obsessive-compulsive disorder are exposure and response prevention therapy and the serotonin reuptake inhibitors. Many patients do not experience complete symptom resolution with either modality and require augmentation approaches. Recent animal and clinical data suggest that D-cycloserine, a partial agonist that acts at the strychnine-insensitive glycine-recognition site of the N-methyl-D-aspartate receptor complex, may enhance extinction learning that occurs in exposure-based psychotherapies. Given this, this study examined if D-cycloserine (250 mg) enhances the overall efficacy and rate of change of exposure and response prevention therapy for adult obsessive-compulsive disorder. Participants were 24 adults meeting Diagnostic and Statistical Manual of Mental Disorders-IV criteria for obsessive-compulsive disorder. The study design was a randomized, double-blinded, placebo-controlled augmentation trial examining exposure and response prevention therapy+D-cycloserine versus exposure and response prevention therapy+placebo. All patients received 12 weekly sessions of exposure and response prevention treatment. The first session involved building a ritual hierarchy and providing psychoeducation about obsessive-compulsive disorder. The second session involved a practice exposure. Sessions 3-12 involved exposure and response prevention exercises. D-cycloserine or placebo (250 mg) was taken 4 h before every session. No significant group differences were found across outcome variables. The rate of improvement did not differ between groups. The present results fail to support the use of D-cycloserine with exposure and response prevention therapy for adult obsessive-compulsive disorder. As this study is the first to explore this question and a number of methodological issues must be considered when interpreting the findings, the conclusions that may be drawn from our results are limited.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The weak or null effects observed in previous studies of pre-session DCS may be accounted for by large individual variability in fear extinction observed in therapy sessions.
“The findings of the present study suggest that the weak or null effects observed in these previous studies may be accounted for by large individual variability in fear extinction observed in therapy sessions.”
From D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia (2013) · cites this paper as [6]
The citation lists haven’t been fetched yet
References 33 · Cited by 200
- Authors
- Storch, E. A., Merlo, L. J., Bengtson, M., Murphy, T. K., Lewis, M. H., Yang, M. C., Jacob, M. L., Larson, M., Hirsh, A., Fernandez, M., Geffken, G. R., & Goodman, W. K.
- Affiliations
- University of Florida Health (US)
- Corresponding author
- Storch, Eric A.
- ORCID
- Venue
- International Clinical Psychopharmacology
- Published
- 2007-07
- Volume
- 22
- Issue
- 4
- Pages
- 230-237
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W1978199448
- Cited by
- 200
- References
- 33
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 4 · 2023: 5 · 2022: 4 · 2021: 6 · 2020: 2 · 2019: 5 · 2018: 5 · 2017: 12 · 2016: 7 · 2015: 17 · 2014: 16 · 2013: 19 · 2012: 21
- FWCI
- 20.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Florida
- National Institutes of Health
- National Institute of Mental Health
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Keywords
- D-cycloserine, obsessive-compulsive disorder, exposure and response prevention, augmentation therapy, NMDA receptor glycine site, extinction learning, treatment efficacy, placebo comparison
- MeSH terms
- Adolescent, Adult, Behavior Therapy, Combined Modality Therapy, Cycloserine, Double-Blind Method, Female, Humans, Male, Middle Aged, Obsessive-Compulsive Disorder, Placebos, Psychiatric Status Rating Scales, Receptors, N-Methyl-D-Aspartate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review